148 related articles for article (PubMed ID: 26990212)
21. Intravenous prophylaxis for paclitaxel-related hypersensitivity reactions.
Bookman MA; Kloth DD; Kover PE; Smolinski S; Ozols RF
Semin Oncol; 1997 Dec; 24(6 Suppl 19):S19-13-S19-15. PubMed ID: 9427258
[TBL] [Abstract][Full Text] [Related]
22. Paclitaxel-associated hypersensitivity reactions: experience of the gynecologic oncology program of the Cleveland Clinic Cancer Center.
Markman M; Kennedy A; Webster K; Kulp B; Peterson G; Belinson J
J Clin Oncol; 2000 Jan; 18(1):102-5. PubMed ID: 10623699
[TBL] [Abstract][Full Text] [Related]
23. H1- and H2-receptor antagonists prevent histamine release in allergic patients after the administration of midazolam-ketamine. A randomized controlled study.
Kimura K; Adachi M; Kubo K
Inflamm Res; 1999 Mar; 48(3):128-32. PubMed ID: 10219654
[TBL] [Abstract][Full Text] [Related]
24. Fatal outcome of a hypersensitivity reaction to paclitaxel: a critical review of premedication regimens.
Kloover JS; den Bakker MA; Gelderblom H; van Meerbeeck JP
Br J Cancer; 2004 Jan; 90(2):304-5. PubMed ID: 14974481
[TBL] [Abstract][Full Text] [Related]
25. [Paclitaxel hypersensitivity reactions in patients with advanced ovarian carcinoma].
Kobierski J; Majdak E; Mielcarek P; Emerich J
Ginekol Pol; 2002 Nov; 73(11):1015-20. PubMed ID: 12722392
[TBL] [Abstract][Full Text] [Related]
26. [Tolerance induction in anaphylaxis to carboplatin].
Herzinger T; Behr J; Przybilla B
Dtsch Med Wochenschr; 2003 Jul; 128(30):1595-6. PubMed ID: 12884147
[No Abstract] [Full Text] [Related]
27. Use of cisplatin without desensitization after carboplatin hypersensitivity reaction in epithelial ovarian and primary peritoneal cancer.
Callahan MB; Lachance JA; Stone RL; Kelsey J; Rice LW; Jazaeri AA
Am J Obstet Gynecol; 2007 Aug; 197(2):199.e1-4; discussion 199.e4-5. PubMed ID: 17689649
[TBL] [Abstract][Full Text] [Related]
28. Premedication strategy in cetuximab rechallenge after Grade 2 hypersensitivity reactions.
Lofy M; Jung L; Dow-Hillgartner E
J Oncol Pharm Pract; 2024 Mar; 30(2):412-416. PubMed ID: 37936371
[TBL] [Abstract][Full Text] [Related]
29. Retreatment with nedaplatin in patients with recurrent gynecological cancer after the development of hypersensitivity reaction to carboplatin.
Arimoto T; Oda K; Nakagawa S; Kawana K; Tsukazaki T; Adachi K; Matsumoto Y; Yano T; Kozuma S; Taketani Y
J Obstet Gynaecol Res; 2013 Jan; 39(1):336-40. PubMed ID: 22690725
[TBL] [Abstract][Full Text] [Related]
30. Feasibility of stopping paclitaxel premedication after two doses in patients not experiencing a previous infusion hypersensitivity reaction.
Berger MJ; Dunlea LJ; Rettig AE; Lustberg MB; Phillips GS; Shapiro CL
Support Care Cancer; 2012 Sep; 20(9):1991-7. PubMed ID: 22089428
[TBL] [Abstract][Full Text] [Related]
31. The added value of H
Cox JM; van Doorn L; Malmberg R; Oomen-de Hoop E; Bosch TM; van den Bemt PMLA; Boere IA; Jager A; Mathijssen RHJ; van Leeuwen RWF
Br J Cancer; 2021 May; 124(10):1647-1652. PubMed ID: 33762718
[TBL] [Abstract][Full Text] [Related]
32. Incidence and risk factors for paclitaxel hypersensitivity during ovarian cancer chemotherapy.
Sendo T; Sakai N; Itoh Y; Ikesue H; Kobayashi H; Hirakawa T; Nakano H; Oishi R
Cancer Chemother Pharmacol; 2005 Jul; 56(1):91-6. PubMed ID: 15791461
[TBL] [Abstract][Full Text] [Related]
33. Carboplatin hypersensitivity reactions.
Winkeljohn D; Polovich M
Clin J Oncol Nurs; 2006 Oct; 10(5):595-8. PubMed ID: 17063613
[TBL] [Abstract][Full Text] [Related]
34. Carboplatin hypersensitivity reactions: re-treatment with cisplatin desensitisation.
Jones R; Ryan M; Friedlander M
Gynecol Oncol; 2003 Apr; 89(1):112-5. PubMed ID: 12694663
[TBL] [Abstract][Full Text] [Related]
35. A comparison of two prophylactic regimens for hypersensitivity reactions to paclitaxel.
Kwon JS; Elit L; Finn M; Hirte H; Mazurka J; Moens F; Trim K
Gynecol Oncol; 2002 Mar; 84(3):420-5. PubMed ID: 11855881
[TBL] [Abstract][Full Text] [Related]
36. Prophylactic 3-hour graduated infusion schedule minimizes risk of carboplatin hypersensitivity reactions - A prospective study.
Koul A; Forsland EL; Bjurberg M
Gynecol Oncol; 2018 Feb; 148(2):363-367. PubMed ID: 29208369
[TBL] [Abstract][Full Text] [Related]
37. Repeat chemonucleolysis.
Sutton JC
Clin Orthop Relat Res; 1986 May; (206):45-9. PubMed ID: 2871956
[TBL] [Abstract][Full Text] [Related]
38. Retrospective evaluation of weekly paclitaxel hypersensitivity reactions reported utilizing an electronic medical record system at a tertiary cancer center.
Lal LS; Gerber DL; Lau J; Dana W
Support Care Cancer; 2009 Oct; 17(10):1311-5. PubMed ID: 19184123
[TBL] [Abstract][Full Text] [Related]
39. Oral premedication for the prevention of hypersensitivity reactions to paclitaxel.
Zidan J; Hussein O; Abzah A; Tamam S; Farraj Z; Friedman E
Med Oncol; 2008; 25(3):274-8. PubMed ID: 18363113
[TBL] [Abstract][Full Text] [Related]
40. Clinical features and management of carboplatin-related hypersensitivity reactions in pediatric low-grade glioma.
Genc DB; Canpolat C; Berrak SG
Support Care Cancer; 2012 Feb; 20(2):385-93. PubMed ID: 21416159
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
